Cargando…
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
Purpose Anticancer agents are known to increase cancer-associated thrombosis (CAT) onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel plus ramucirumab combination therapy, and 11.9% in bevacizumab monotherapy. Because immune checkpoint inhibitors (ICIs) caus...
Autores principales: | Ando, Yosuke, Hayashi, Takahiro, Sugimoto, Reiko, Nishibe, Seira, Ito, Kaori, Kawada, Kenji, Ikeda, Yoshiaki, Yamada, Shigeki, Imaizumi, Kazuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340643/ https://www.ncbi.nlm.nih.gov/pubmed/31823160 http://dx.doi.org/10.1007/s10637-019-00881-6 |
Ejemplares similares
-
Effect of renal function on pemetrexed-induced haematotoxicity
por: Ando, Yosuke, et al.
Publicado: (2016) -
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer
por: Ohta, Hideki, et al.
Publicado: (2017) -
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015) -
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma
por: Tomono, Ayana, et al.
Publicado: (2016) -
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
por: Matsuoka, Hiroshi, et al.
Publicado: (2020)